Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.

With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local ...

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

Steven H. Stein currently works at Repare Therapeutics, Inc., as Director from 2024, Incyte Corp., as Chief Medical Officer & Executive Vice President from 2016, the University of Pennsylvania, as ...

Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., (GLOBE ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

2025 – Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncology (ASCO) ...

Swiss pharma giant Novartis (NOVN: VX) will spotlight key data across its oncology portfolio, including Kisqali (ribociclib), Scemblix (asciminib) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), ...

aDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre ... Merck, Nektar Therapeutics, Novartis, PTC Therapeutics, Seattle Genetics, Servier, Sanofi, and Mersana, outside of the ...

Verastem Oncology said the Food and Drug Administration approved the combination of avutometinib capsules and defactinib tablets for certain patients with KRAS-mutated recurrent low-grade serous ...